| Chemotherapy-induced nausea and vomiting
Sancuso vs Syndros
Side-by-side clinical, coverage, and cost comparison for chemotherapy-induced nausea and vomiting.Deep comparison between: Sancuso vs Syndros with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSyndros has a higher rate of injection site reactions vs Sancuso based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Syndros but not Sancuso, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sancuso
Syndros
At A Glance
Transdermal
Single patch, up to 7 days
5-HT3 receptor antagonist
Oral
Cannabinoid
Indications
- Chemotherapy-induced nausea and vomiting
- Anorexia
- Chemotherapy-induced nausea and vomiting
Dosing
Chemotherapy-induced nausea and vomiting Apply a single transdermal system to the upper outer arm 24-48 hours before chemotherapy; wear for at minimum 24 hours after chemotherapy is completed, up to 7 days total; each system releases 3.1 mg granisetron per 24 hours.
Anorexia 2.1 mg orally twice daily, one hour before lunch and one hour before dinner; may titrate up to 4.2 mg before lunch and 4.2 mg before dinner; maximum 8.4 mg twice daily.
Chemotherapy-induced nausea and vomiting 4.2 mg/m2 orally 1 to 3 hours prior to chemotherapy, then every 2 to 4 hours after chemotherapy for 4 to 6 doses per day; may titrate in increments of 2.1 mg/m2; maximum 12.6 mg/m2 per dose.
Contraindications
- Known hypersensitivity to granisetron or any component of the transdermal system
- History of hypersensitivity reaction to dronabinol
- History of hypersensitivity reaction to alcohol
- Concurrent or recent use of disulfiram- or metronidazole-containing products within 14 days
Adverse Reactions
Most common (>=3%) Constipation, headache
Serious Progressive ileus and gastric distention, serotonin syndrome, skin reactions, increased drug exposure with external heat sources, phototoxicity with ultraviolet light exposure
Postmarketing Application site reactions (pain, pruritus, erythema, rash, irritation, vesicles, burn, discoloration, urticaria), transdermal system non-adhesion, bradycardia, chest pain, palpitations, sick sinus syndrome
Most common (>=3%) abdominal pain, dizziness, euphoria, nausea, paranoid reaction, somnolence, thinking abnormal, vomiting
Serious neuropsychiatric adverse reactions, hemodynamic instability, seizures, paradoxical nausea/vomiting/abdominal pain, toxicity in preterm neonates
Postmarketing fatigue, hypersensitivity reactions (lip swelling, hives, rash), fall, seizures, disorientation, movement disorder, loss of consciousness, delirium, insomnia, panic attack, syncope
Pharmacology
Granisetron is a selective 5-HT3 receptor antagonist that blocks serotonin-3 receptors located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone, preventing chemotherapy-induced serotonin release from stimulating the vomiting reflex.
Dronabinol is an orally active cannabinoid that exerts complex effects on the CNS, including central sympathomimetic activity, mediated through cannabinoid receptors in neural tissues.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sancuso
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (1/12) · Qty limit (9/12)
Syndros
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
UnitedHealthcare
Sancuso
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (2/8)
Syndros
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Sancuso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Syndros
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Sancuso.
Cost estimate not availableHealthWell: Chemotherapy Induced Nausea or Vomiting - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SancusoView full Sancuso profile
SyndrosView full Syndros profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.